Boehringer Ingelheim and Eli Lilly received Marketing Authorization from the European Commission for linagliptin 5 mg film-coated tablets (to be marketed under the trade name Trajenta® in Europe) for the treatment of adults with type 2 diabetes.
The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea.
Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
http://www.prnewswire.com/news-rele...e-treatment-of-type-2-diabetes-128405173.html
The European Commission has approved linagliptin in combination with metformin and metformin plus sulfonylurea.
Linagliptin is also approved for use as monotherapy in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due to intolerance, or contraindicated due to renal impairment.
http://www.prnewswire.com/news-rele...e-treatment-of-type-2-diabetes-128405173.html
